LEADER 02575oam 2200757 450 001 9910709758903321 005 20190204152659.0 035 $a(CKB)5470000002472657 035 $a(OCoLC)1042073861 035 $a(EXLCZ)995470000002472657 100 $a20180627d2018 ua 0 101 0 $aeng 135 $aurbn||||a|||| 181 $ctxt$2rdacontent 182 $cc$2rdamedia 183 $acr$2rdacarrier 200 10$aAntitrust concerns and the FDA approval process $ehearing before the Subcommittee on Regulatory Reform, Commercial and Antitrust Law of the Committee on the Judiciary, House of Representatives, One Hundred Fifteenth Congress, first session, July 27, 2017 210 1$aWashington :$cU.S. Government Publishing Office,$d2018. 215 $a1 online resource (iv, 51 pages) 300 $a"Serial no. 115-27." 517 $aAntitrust concerns and the FDA approval process 606 $aDrugs$zUnited States$xTesting 606 $aDrug approval$zUnited States 606 $aDrugs$xSafety regulations$zUnited States 606 $aMedical instruments and apparatus$xSafety regulations$zUnited States 606 $aGeneric drugs$zUnited States 606 $aCompetition$zUnited States 606 $aAntitrust law$zUnited States 606 $aAntitrust law$2fast 606 $aCompetition$2fast 606 $aDrug approval$2fast 606 $aDrugs$xSafety regulations$2fast 606 $aDrugs$xTesting$2fast 606 $aGeneric drugs$2fast 606 $aMedical instruments and apparatus$xSafety regulations$2fast 607 $aUnited States$2fast 608 $aLegislative hearings.$2fast 608 $aRules.$2fast 608 $aLegislative hearings.$2lcgft 615 0$aDrugs$xTesting. 615 0$aDrug approval 615 0$aDrugs$xSafety regulations 615 0$aMedical instruments and apparatus$xSafety regulations 615 0$aGeneric drugs 615 0$aCompetition 615 0$aAntitrust law 615 7$aAntitrust law. 615 7$aCompetition. 615 7$aDrug approval. 615 7$aDrugs$xSafety regulations. 615 7$aDrugs$xTesting. 615 7$aGeneric drugs. 615 7$aMedical instruments and apparatus$xSafety regulations. 801 0$bGPO 801 1$bGPO 801 2$bGPO 801 2$bMERUC 801 2$bOCLCF 801 2$bINT 801 2$bOCLCQ 801 2$bOCLCO 801 2$bGPO 906 $aBOOK 912 $a9910709758903321 996 $aAntitrust concerns and the FDA approval process$93518873 997 $aUNINA